Coronary computed tomography angiography vs functional stress imaging to triage chest pain in the emergency room?
Vascul Pharmacol. 2023 Dec 28;154:107272. doi: 10.1016/j.vph.2023.107272. Online ahead of print.ABSTRACTIn patients with a suspected acute coronary syndrome, non-elevated (or uncertain) (NSTE-ACS) high sensitivity cardiac troponin, no ECG changes and no recurrence of chest pain, incorporating a coronary computed tomography angiogram (CCTA) or a non-invasive functional stress imaging test as part of the initial workup should be considered (Class IIA, Level of Evidence A). There are pros and cons with each diagnostic approach. CCTA imaging has high sensitivity for detecting coronary atherosclerosis but may not provide a diag...
Source: Vascular Pharmacology - December 30, 2023 Category: Drugs & Pharmacology Authors: Colin Berry Source Type: research
Therapy and guideline adherence at a multidisciplinary hypertension clinic: A prospective, observational study
CONCLUSION: A visit to the multidisciplinary hypertension clinic improved prescriber guideline compliance and the use of single pill combinations. Involvement of a clinical pharmacist could be beneficial to further improve patient drug therapy adherence and guideline compliance.PMID:38159830 | DOI:10.1016/j.vph.2023.107271 (Source: Vascular Pharmacology)
Source: Vascular Pharmacology - December 30, 2023 Category: Drugs & Pharmacology Authors: Julie Hias Lise Defieuw Thomas Vanassche Peter Verhamme Lorenz Van der Linden Source Type: research
Coronary computed tomography angiography vs functional stress imaging to triage chest pain in the emergency room?
Vascul Pharmacol. 2023 Dec 28;154:107272. doi: 10.1016/j.vph.2023.107272. Online ahead of print.ABSTRACTIn patients with a suspected acute coronary syndrome, non-elevated (or uncertain) (NSTE-ACS) high sensitivity cardiac troponin, no ECG changes and no recurrence of chest pain, incorporating a coronary computed tomography angiogram (CCTA) or a non-invasive functional stress imaging test as part of the initial workup should be considered (Class IIA, Level of Evidence A). There are pros and cons with each diagnostic approach. CCTA imaging has high sensitivity for detecting coronary atherosclerosis but may not provide a diag...
Source: Vascular Pharmacology - December 30, 2023 Category: Drugs & Pharmacology Authors: Colin Berry Source Type: research
Therapy and guideline adherence at a multidisciplinary hypertension clinic: A prospective, observational study
CONCLUSION: A visit to the multidisciplinary hypertension clinic improved prescriber guideline compliance and the use of single pill combinations. Involvement of a clinical pharmacist could be beneficial to further improve patient drug therapy adherence and guideline compliance.PMID:38159830 | DOI:10.1016/j.vph.2023.107271 (Source: Vascular Pharmacology)
Source: Vascular Pharmacology - December 30, 2023 Category: Drugs & Pharmacology Authors: Julie Hias Lise Defieuw Thomas Vanassche Peter Verhamme Lorenz Van der Linden Source Type: research
Coronary computed tomography angiography vs functional stress imaging to triage chest pain in the emergency room?
Vascul Pharmacol. 2023 Dec 28;154:107272. doi: 10.1016/j.vph.2023.107272. Online ahead of print.ABSTRACTIn patients with a suspected acute coronary syndrome, non-elevated (or uncertain) (NSTE-ACS) high sensitivity cardiac troponin, no ECG changes and no recurrence of chest pain, incorporating a coronary computed tomography angiogram (CCTA) or a non-invasive functional stress imaging test as part of the initial workup should be considered (Class IIA, Level of Evidence A). There are pros and cons with each diagnostic approach. CCTA imaging has high sensitivity for detecting coronary atherosclerosis but may not provide a diag...
Source: Vascular Pharmacology - December 30, 2023 Category: Drugs & Pharmacology Authors: Colin Berry Source Type: research
Inflammation and the pathogenesis of atherosclerosis
Vascul Pharmacol. 2023 Dec 28;154:107255. doi: 10.1016/j.vph.2023.107255. Online ahead of print.ABSTRACTThe notion that inflammation contributes to atherosclerosis has now gained considerable currency. Inflammation participates in atherosclerosis inception, progression, and thrombotic complications. Induced expression of endothelial leukocyte adhesion molecules and chemoattractant cytokines recruit blood cells to the arterial intima. Lesions can contain virtually every type of leukocyte. Monocytes mature into macrophages and imbibe lipids becoming foam cells, a hallmark of the atherosclerotic lesion. T lymphocytes can inst...
Source: Vascular Pharmacology - December 29, 2023 Category: Drugs & Pharmacology Authors: Peter Libby Source Type: research
Prime editing in mice with an engineered pegRNA
Vascul Pharmacol. 2023 Dec 27:107269. doi: 10.1016/j.vph.2023.107269. Online ahead of print.ABSTRACTCRISPR editing involves double-strand breaks in DNA with attending insertions/deletions (indels) that may result in embryonic lethality in mice. The prime editing (PE) platform uses a prime editing guide RNA (pegRNA) and a Cas9 nickase fused to a modified reverse transcriptase to precisely introduce nucleotide substitutions or small indels without the unintended editing associated with DNA double-strand breaks. Recently, engineered pegRNAs (epegRNAs), with a 3'-extension that shields the primer-binding site of the pegRNA fro...
Source: Vascular Pharmacology - December 29, 2023 Category: Drugs & Pharmacology Authors: Amr R Salem W Bart Bryant Jaser Doja Susan H Griffin Xiaofan Shi Weihong Han Yunchao Su Alexander D Verin Joseph M Miano Source Type: research
Adipsin in the pathogenesis of cardiovascular diseases
Vascul Pharmacol. 2023 Dec 17;154:107270. doi: 10.1016/j.vph.2023.107270. Online ahead of print.ABSTRACTAdipsin is an adipokine predominantly synthesized in adipose tissues and released into circulation. It is also known as complement factor-D (CFD), acting as the rate-limiting factor in the alternative complement pathway and exerting essential functions on the activation of complement system. The deficiency of CFD in humans is a very rare condition. However, complement overactivation has been implicated in the etiology of numerous disorders, including cardiovascular disease (CVD). Increased circulating level of adipsin ha...
Source: Vascular Pharmacology - December 19, 2023 Category: Drugs & Pharmacology Authors: Ayobami Dare Shi-You Chen Source Type: research
Adipsin in the pathogenesis of cardiovascular diseases
Vascul Pharmacol. 2023 Dec 17;154:107270. doi: 10.1016/j.vph.2023.107270. Online ahead of print.ABSTRACTAdipsin is an adipokine predominantly synthesized in adipose tissues and released into circulation. It is also known as complement factor-D (CFD), acting as the rate-limiting factor in the alternative complement pathway and exerting essential functions on the activation of complement system. The deficiency of CFD in humans is a very rare condition. However, complement overactivation has been implicated in the etiology of numerous disorders, including cardiovascular disease (CVD). Increased circulating level of adipsin ha...
Source: Vascular Pharmacology - December 19, 2023 Category: Drugs & Pharmacology Authors: Ayobami Dare Shi-You Chen Source Type: research
Adipsin in the pathogenesis of cardiovascular diseases
Vascul Pharmacol. 2023 Dec 17;154:107270. doi: 10.1016/j.vph.2023.107270. Online ahead of print.ABSTRACTAdipsin is an adipokine predominantly synthesized in adipose tissues and released into circulation. It is also known as complement factor-D (CFD), acting as the rate-limiting factor in the alternative complement pathway and exerting essential functions on the activation of complement system. The deficiency of CFD in humans is a very rare condition. However, complement overactivation has been implicated in the etiology of numerous disorders, including cardiovascular disease (CVD). Increased circulating level of adipsin ha...
Source: Vascular Pharmacology - December 19, 2023 Category: Drugs & Pharmacology Authors: Ayobami Dare Shi-You Chen Source Type: research
Adipsin in the pathogenesis of cardiovascular diseases
Vascul Pharmacol. 2023 Dec 17;154:107270. doi: 10.1016/j.vph.2023.107270. Online ahead of print.ABSTRACTAdipsin is an adipokine predominantly synthesized in adipose tissues and released into circulation. It is also known as complement factor-D (CFD), acting as the rate-limiting factor in the alternative complement pathway and exerting essential functions on the activation of complement system. The deficiency of CFD in humans is a very rare condition. However, complement overactivation has been implicated in the etiology of numerous disorders, including cardiovascular disease (CVD). Increased circulating level of adipsin ha...
Source: Vascular Pharmacology - December 19, 2023 Category: Drugs & Pharmacology Authors: Ayobami Dare Shi-You Chen Source Type: research
Adipsin in the pathogenesis of cardiovascular diseases
Vascul Pharmacol. 2023 Dec 17;154:107270. doi: 10.1016/j.vph.2023.107270. Online ahead of print.ABSTRACTAdipsin is an adipokine predominantly synthesized in adipose tissues and released into circulation. It is also known as complement factor-D (CFD), acting as the rate-limiting factor in the alternative complement pathway and exerting essential functions on the activation of complement system. The deficiency of CFD in humans is a very rare condition. However, complement overactivation has been implicated in the etiology of numerous disorders, including cardiovascular disease (CVD). Increased circulating level of adipsin ha...
Source: Vascular Pharmacology - December 19, 2023 Category: Drugs & Pharmacology Authors: Ayobami Dare Shi-You Chen Source Type: research
Adipsin in the pathogenesis of cardiovascular diseases
Vascul Pharmacol. 2023 Dec 17;154:107270. doi: 10.1016/j.vph.2023.107270. Online ahead of print.ABSTRACTAdipsin is an adipokine predominantly synthesized in adipose tissues and released into circulation. It is also known as complement factor-D (CFD), acting as the rate-limiting factor in the alternative complement pathway and exerting essential functions on the activation of complement system. The deficiency of CFD in humans is a very rare condition. However, complement overactivation has been implicated in the etiology of numerous disorders, including cardiovascular disease (CVD). Increased circulating level of adipsin ha...
Source: Vascular Pharmacology - December 19, 2023 Category: Drugs & Pharmacology Authors: Ayobami Dare Shi-You Chen Source Type: research
Adipsin in the pathogenesis of cardiovascular diseases
Vascul Pharmacol. 2023 Dec 17;154:107270. doi: 10.1016/j.vph.2023.107270. Online ahead of print.ABSTRACTAdipsin is an adipokine predominantly synthesized in adipose tissues and released into circulation. It is also known as complement factor-D (CFD), acting as the rate-limiting factor in the alternative complement pathway and exerting essential functions on the activation of complement system. The deficiency of CFD in humans is a very rare condition. However, complement overactivation has been implicated in the etiology of numerous disorders, including cardiovascular disease (CVD). Increased circulating level of adipsin ha...
Source: Vascular Pharmacology - December 19, 2023 Category: Drugs & Pharmacology Authors: Ayobami Dare Shi-You Chen Source Type: research
Adipsin in the pathogenesis of cardiovascular diseases
Vascul Pharmacol. 2023 Dec 17;154:107270. doi: 10.1016/j.vph.2023.107270. Online ahead of print.ABSTRACTAdipsin is an adipokine predominantly synthesized in adipose tissues and released into circulation. It is also known as complement factor-D (CFD), acting as the rate-limiting factor in the alternative complement pathway and exerting essential functions on the activation of complement system. The deficiency of CFD in humans is a very rare condition. However, complement overactivation has been implicated in the etiology of numerous disorders, including cardiovascular disease (CVD). Increased circulating level of adipsin ha...
Source: Vascular Pharmacology - December 19, 2023 Category: Drugs & Pharmacology Authors: Ayobami Dare Shi-You Chen Source Type: research
